In vitro fl uorogenic assays of CETP-mediated CE and TG transfer
For determination of in vitro CETP transfer activity, a continuous fl uorogenic assay described previously ( 64 ) was used. In brief, this assay measures the CE or TG transfer half-reaction using a synthetic donor particle similar in size and density to HDL-C, which bears a core of fl uorescent CE or TG. The high Transgenic mice carrying either the human or cynomolgus monkey CETP gene have dramatically lower HDL-C levels and are more susceptible to diet-induced atherosclerosis ( 28, 29 ) . In the context of hypertriglyceridemia, however, transgenic expression of CETP was shown to reduce atherosclerosis despite lower HDL-C levels ( 30, 31 ) . In contrast to mice, rabbits have CETP activity levels comparable to humans and are prone to diet-induced atherosclerosis ( 32 ) . Inhibition of CETP in rabbits via the administration of anti-CETP monoclonal antibodies, anti-sense oligonucleotides, small molecules, or vaccineinduced antibodies results in increased HDL-C levels and a decrease in atherosclerosis (33) (34) (35) (36) .
Interest in CETP as a therapeutic target for raising HDL-C began with the discovery of genetic CETP defi ciency in a small Japanese population with hyperalphalipoproteinemia or very high HDL-C levels (37) (38) (39) . However, fi ndings regarding the relationship between CETP defi ciency and CHD risk have been confl icting, indicating either an increase ( 40 ) or decrease ( 41 ) in CHD risk. Several reports describing single nucleotide polymorphisms (SNPs) within CETP and their effect on CETP activity and expression levels, in addition to HDL-C concentrations, have been described, illustrating a key role of CETP in regulating circulating HDL-C levels in humans (42) (43) (44) (45) . Whereas the relationship between SNPs within CETP and both CETP and HDL-C levels has been established, fi ndings regarding the infl uence of such SNPs on CHD risk remain inconsistent (45) (46) (47) (48) (49) . Therefore, to fi rmly establish a causal link between CETP and CHD risk, either additional genetic analyses with larger populations of individuals or pharmacological inhibition of CETP will be required.
To date, clinical studies with 3 CETP inhibitors have been reported, including anacetrapib, torcetrapib, and dalcetrapib. Torcetrapib is a potent inhibitor of CETP transfer activity, presumably through the formation of a complex between CETP and HDL ( 50 ) . Although treatment with torcetrapib in humans signifi cantly elevates HDL-C and lowers LDL-C levels ( 51, 52 ) , its clinical development recently ended due to an increase in both mortality and morbidity rates in the active treatment group compared with the placebo group within the ILLUMI-NATE trial ( 53 ) . Following termination of the ILLUMI-NATE trial, it was found that treatment with torcetrapib results in increased systolic blood pressure, increased levels of serum aldosterone, sodium, and bicarbonate, and decreased serum potassium levels ( 53 ) . Preclinical studies have clearly demonstrated that the effect of torcetrapib on blood pressure and aldosterone release is the result of molecule-specifi c, off-target effects; these effects have not been observed with anacetrapib or dalcetrapib ( 54, 55 ) . Dalcetrapib is an inhibitor of CETP transfer activity and is currently in phase III clinical studies ( 35 ) . Inhibition of CETP by dalcetrapib requires formation of a covalent disulfi de bond with Cys13 of CETP ( 35, 56 ) . Treatment of humans with dalcetrapib results in increases in HDL-C (19-37%) and a modest decrease ( ‫ف‬ 6%) in LDL-C levels ( 57 ) . Anacetrapib is an inhibitor of CETP transfer activity and is currently in phase III clinical studies ( 58 ) . Treatby guest, on August 28, 2017 www.jlr.org Downloaded from upon bound ligand was separated from free by processing 80 l on a Pierce Zeba TM 96-well Desalt Spin Plate (Pierce) according to the manufacturer's instructions. The 50 l of the column eluate containing CETP and bound inhibitor was quantitated in 5 ml Perkin Elmer Ultima Gold MV using a Perkin Elmer TriCarb 2900TR liquid scintillation analyzer. Specifi c binding was calculated as the difference between the amount of inhibitor bound in the presence of CETP (eluate) minus the amount of inhibitor bound in the absence of CETP (eluate). Similar levels of nonspecifi c binding were observed in reactions lacking CETP or in which an excess of unlabeled torcetrapib (1 uM) or an unrelated protein (prolylcarboxypeptidase) was added, indicating that the binding observed with CETP was specifi c (data not shown).
Liquid chromatography-mass spectrometry of covalent modifi cation of CETP N341Q CETP (18 M) was incubated with either 120 M dalcetrapib disulfi de inhibitor or anacetrapib in 50 mM Tris, pH 7.5, with 150 mM NaCl for 36 h at room temperature. Intact mass spectra were collected by ultra performance (UP) LC-MS using a polyhydroxyethyl A column (100 × 2.1 mm; 5 , 1,000 Å) from PolyLC Inc. (Columbia, MD) running isocratically at 0.05 ml/min on a Waters Acquity with a Synapt mass spectrometer. The UPLC solvent was 0.1% formic acid, 1% m-nitrobenzyl alcohol in 20% acetonitrile. For reactions containing DTT, 10 mM DTT was added to samples after the 36 h incubation with dalcetrapib and incubated for an additional 1 h at room temperature. For reactions containing iodoacetamide, a fi nal concentration of 10 mM iodoacetamide was incubated with CETP for 6 h at room temperature.
In vitro covalent reaction of CETP inhibitors with human and mouse plasma proteins
The covalent labeling of bulk plasma proteins by CETP inhibitors was assessed using a method similar to those previously reported ( 66 ) . [ 14 C-phenyl]dalcetrapib and [ 14 C]anacetrapib (at 3, 10, and 50 M fi nal concentration) were incubated at 37°C with pooled fresh human or mouse plasma for 0, 0.5, 1, 2, 16, and 24 h. At the end of each incubation time, aliquots of plasma in triplicate were quenched with 2 ml of acetonitrile. Samples were vortex mixed, refrigerated to precipitate the protein, and centrifuged at 1800 g for 15 min. The supernatant was discarded, and the protein pellet was saved for subsequent washings. Then 1 ml of distilled and deionized water was added to each pellet and the samples were sequentially sonicated and vortex mixed for 10 min each. Absolute ethanol (4 ml) was added to the samples and the tubes were vortex mixed again for 10 min. The samples were then refrigerated again to reprecipitate the protein, centrifuged, and the supernatant was discarded. The above washing sequence was repeated until the radioactivity in the washings was near background levels. After the fi nal washing, the protein pellet was dissolved in 0.7 ml of 0.1 N NaOH by gentle vortex mixing. The radioactivity content in a 0.2 ml aliquot of the pellet solution was determined by direct liquid scintillation counting following neutralization with 0.2 ml of 0.1 N HCl. Protein concentrations in the pellet solution were measured using the Pierce protein assay kit. The fi nal amount of 14 C radioactivity irreversibly bound to proteins was expressed as pmol-equivalent bound/mg of protein.
For SDS-PAGE analysis of protein labeling, the binding method was also modifi ed from those previously reported ( 66 ) . ]anacetrapib (at 50 M fi nal concentration) were incubated at 37°C with pooled fresh human or mouse plasma for 2 and 24 h. Identical experiments were performed with fresh plasma from humans and either wild-type C57Bl/6 mice or from C57Bl/6 mice carrying the cynomolgus monkey CETP gene ( 28 ) . At each time point, aliquots of human or mouse concentration of Bodipy®-CE or Bodipy®-TG and the addition of DabcylN(C18) (in the case of the CE donor particles only) cause quenching of the fl uorescent signal in the donor particles. Native VLDLs and LDLs are used as an acceptor. As a molecule of fl uorescent substrate is removed from the donor and transferred to an acceptor, it escapes quench and becomes fully fl uorescent. Compounds were preincubated with CETP and HDL donor particles for either 1 or 24 h before addition of VLDL/ LDL acceptor particles.
In vitro radioactive assays of CETP-mediated CE and TG transfer Reagents ( 65 ) . The assays were performed by incubating human serum with or without inhibitors at 37°C for 1 h. The [ 3 H] labeled exogenous LDL was then added to the reaction for 60 min at 37°C. The transfer reaction was terminated by precipitation of LDL with 20% w/v PEG 8000. The samples were centrifuged and an aliquot of the HDL-containing supernatant was counted by liquid scintillation. Counts present in the supernatant for controls (incubated at 4°C) were subtracted from those incubated at 37°C to correct for nonspecifi c transfer.
The ability of inhibitors to block CETP-mediated CE and TG transfer was also measured by radioactive CETP transfer assay with 2% human serum. The procedure was similar to the 95% human serum transfer assay described above, except that purifi ed human HDL (128 µg/ml) and 4 , 100 nM NaCl, and 1 mM EDTA) with 2% human serum. The transfer reaction was terminated by precipitation of LDL with 1 vol of ice-cold human serum and 2 vols of 20% w/v PEG 8000. The samples were centrifuged and an aliquot of the HDL-containing supernatant was counted by liquid scintillation. Counts present in the supernatant for controls (without CETP addition) were subtracted from those reactivated with CETP to correct for nonspecifi c transfer.
CETP inhibitor binding assay
The saturable and specifi c binding of [ 3 H]labeled inhibitors to purifi ed CETP and their ability to compete with other inhibitors was determined as follows. Assay conditions similar to the in vitro fl uorogenic CE transfer assay ( 64 ) were chosen to allow direct comparison of an inhibitor's binding and biochemical activity. Binding assays contained 1× CETP buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA) with 0.005% Tween20, and 20 nM purifi ed recombinant CETP in a 100 l fi nal volume. Sheep serum, lacking endogenous CETP, at a fi nal concentration of 2% was added to act as a carrier. Final concentrations of [ high HDL was incubated with or without CETP inhibitor for 1 h at 37°C. A 500 l aliquot was injected inline to dual Superose 6 10/300 GL columns (GE Healthcare) connected in tandem. The plasma was fractionated by FPLC at 4°C using an AKTA Purifi er (GE Healthcare). To obtain good recovery of CETP from plasma fractionated by FPLC, a low ionic strength buffer was used (65 mM sucrose, 225 mM mannitol, 10 mM Tris, pH 7.4, and 1 mM EDTA) as the eluent at a fl ow rate of 0.2 ml/min. Then 0.5 ml fractions were collected after the injection loop was emptied with 2.5 ml of buffer.
Total cholesterol was assayed using the Wako Total Cholesterol E kit per the manufacturer's protocol in fractions collected between 10 and 50 ml.
CETP was assayed in the same fractions using a CETP Delfi a ELISA. Microfl our 2 plates (ThermoLabsystems) were coated with 50 l 4 g/ml anti-TP20 (Ottawa Heart Institute) overnight at 4°C. The FPLC fractions and human serum CETP standards (Wako CETP kit) were treated with SDS (fi nal concentration 0.25%) for 1 h at 37°C. The detection antibody was 50 l of 4 g/ ml biotinylated anti-TP2 (Ottawa Heart Institute) followed by the addition of DELFIA® Eu-Labeled Streptavidin diluted in Delfi a Assay Buffer. Delfi a Enhance solution was added and read in the Envision 2104 Multilabel Reader (Perkin Elmer).
RESULTS

Anacetrapib is a potent inhibitor of CETP neutral lipid transfer activity
Anacetrapib has been shown to inhibit CETP activity, thereby signifi cantly raising HDL-C levels in humans ( 59, 61, 67 ) . However, a description of anacetrapib's biochemical characterization and mechanism of CETP inhibition has not been reported. To better understand both the similarities and differences between anacetrapib and two additional CETP inhibitors, torcetrapib and dalcetrapib, we characterized each inhibitor in a series of biochemical assays. Although each CETP inhibitor increases circulating HDL-C levels in humans, anacetrapib is structurally distinct from both torcetrapib and dalcetrapib. We fi rst compared the relative potencies of each inhibitor in reducing CETP neutral lipid transfer activity using a fl uorogenic CETP assay ( Table 1 ) ( 64 ). As shown in Fig. 1A , anacetrapib is a potent inhibitor of the CETP-dependent transfer of CE (IC 50 = 17 ± 4.8 nM). Torcetrapib inhibited CE transfer with a similar potency (IC 50 = 13 ± 2.7 nM), whereas dalcetrapib displayed a 70-to 80-fold weaker potency in inhibiting CE transfer (IC 50 = 1,178 ± 443 nM). The potencies of these compounds in inhibiting CETP-dependent TG transfer were similar to those observed with CE transfer, indicating that each compound blocked both CE and TG transfer activities of CETP ( Fig. 1B , Table 1 ). We next determined if the ability of these compounds to inhibit CETP-mediated transfer of CE was time dependent by preincubating each compound with CETP and HDL donor particles for 24 h prior to the addition of VLDL/LDL acceptor particles. The potencies of both anacetrapib (IC 50 = 13 ± 1.4 nM) and torcetrapib (IC 50 = 14 ± 0.7 nM) in inhibiting CE transfer were not signifi cantly different than when preincubated for only 1 h ( Fig. 1C ) . In contrast, dalcetrapib was 26-fold more potent (IC 50 = 45 ± 2.1 nM) in inhibiting CETP-mediated transfer of CE when preincubated for 24 h ( Fig. 1C ) . plasma in triplicate were diluted to a fi nal volume of 1,275 l with ultrapure water and precipitated with 225 l of tricholoracetic acid. Samples were mixed and stored on ice for 30 min to precipitate the protein and centrifuged at 1,700 g for 5 min. The supernatant was discarded and the protein pellet was saved for subsequent washings. Then 1 ml of ice-cold acetone was added to each pellet, and the samples were sequentially sonicated and vortexed, centrifuged for 5 min and the supernatant was discarded. The above washing sequence was repeated until the radioactivity in the washings was near background levels. After the fi nal washing, one of the triplicates was saved for covalent binding determination and the other two were prepared for SDS-PAGE analysis. For covalent binding determination, the protein pellets were dissolved in 0.3 ml of 0.1 N NaOH by gentle vortex mixing. The radioactivity content in a 0.15 ml aliquot of the pellet solution was determined by direct liquid scintillation counting following neutralization with 0.15 ml of 0.1 N HCl. Protein concentrations in the pellet solution were measured using the Pierce protein assay kit (Pierce). The fi nal amount of 14 C radioactivity irreversibly bound to proteins was expressed as pmol-equivalent bound/mg protein. For SDS-PAGE analysis, the remaining acetone over the protein pellets was air dried and proteins were solubilized in 7 M urea, 2 M thiourea, and 4% CHAPS for 30 min at room temperature with occasional vortexing. Samples were ultracentrifuged at 50,000 rpm for 30 min at 4°C (Beckman TL-100). Cleared lysates were transferred to fresh tubes, and proteins were quantifi ed with Bradford reagent (Bio-Rad). Samples of equal protein amounts were loaded onto 10-20 or 8% Tris-glycine SDS-PAGE gels (Invitrogen) using a nonreducing 4× Laemmli SDS-Sample buffer (Boston BioProducts). For radioactivity detection, gels were stained with GelCode (Thermo Scientifi c), destained in water, incubated in Amplify (GE Healthcare) for 30 min, and dried using the DryEase mini-gel drying system (Invitrogen). Dried gels were exposed for 12 days to a storage phosphor screen, and signal was detected using the Typhoon 9400 (GE Healthcare). For Western blots, proteins were transferred from gels onto a nitrocellulose fi lter. CETP was detected by fi rst blocking the membrane with TBS containing 0.1% Tween (TBST) and 1% BSA. The blot was then incubated with the mouse TP2 anti-CETP antibody (Ottawa Heart Institute Research Corp., Canada) in TBST with 1% BSA overnight, washed with TBST, incubated with an anti-mouse-AP secondary antibody (Promega) for 1 h, and lastly washed with TBST. Detection was performed with the 1-step NBT/BCIP reagent for 15 min.
CETP-HDL interaction gel mobility shift assay
Reagents were obtained from commercial sources: CETP TP2 (Ottawa Heart Institute Research Corp.,), ECL anti-mouse IgG-HRP (GE Healthcare), and ECL plus detection system (GE Healthcare).
To measure binding of CETP to HDL induced by inhibitors, the electrophoretic mobility of CETP in the presence of HDL was examined by native gel electrophoresis followed by Western blotting. The assays were performed by incubating mixtures of purifi ed N341Q CETP (30 nM) and density-purifi ed HDL (128 ng/ l) with or without inhibitors at 37°C for 1 h. The 4-12% Tris-glycine gels were run at 125 V for 2 h and then electro-blotted to nitrocellulose membrane by iBlot (Invitrogen) dry transfer. The blots were blocked in 5% nonfat milk in 0.1% Tween 20 in PBS (PBST), washed with PBST, probed with the primary CETP TP2 antibody in PBST for 1 h, washed, incubated with HRP-coupled anti-mouse IgG secondary antibody, and then developed with ECL plus detection system.
FPLC fractionation of human plasma
CETP distribution in human plasma was examined using gel fi ltration chromatography. Human plasma from a donor with by guest, on August 28, 2017 www.jlr.org
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Together, these results indicate that both anacetrapib and torcetrapib are potent inhibitors of CETP neutral lipid transfer activity. In addition, dalcetrapib was shown to be a less potent inhibitor of CETP activity and displayed a timedependence of inhibition and a signifi cant loss of potency when tested in 95% human serum.
Anacetrapib and dalcetrapib compete with torcetrapib for binding CETP
Binding of torcetrapib to CETP has previously been demonstrated using either a [ 3 H]torcetrapib-CETP binding assay ( 50 ) or by surface plasmon resonance (Biacore) ( 56 ) . To measure the specifi c binding of anacetrapib to CETP, we used a similar assay with purifi ed CETP protein and either [ 3 H]anacetrapib or [ 3 H]torcetrapib. Recombinant human CETP containing a N341Q substitution was expressed in Drosophila S2 cells and purifi ed to homogeneity ( Fig. 3A ) . The N341Q substitution was engineered to reduce the complexity of CETP glycosylation ( 62 ) . The purifi ed N341Q protein was found to be identical to wildtype CETP in its specifi c activity of CE and TG transfer in addition to its relative sensitivity to various CETP inhibitors [ (62) ( Fig. 3B , Table 1 ).
Using the direct binding assay, we next determined if each CETP inhibitor competes with one another for binding CETP ( Fig. 4 ) The potency of each inhibitor in reducing CETP neutral lipid transfer activity was next determined using a radioactive neutral lipid transfer assay in either 2 or 95% human serum ( Fig. 2 , Table 2 ). When tested in 2% human serum, we found that the relative potency of each inhibitor was similar in both the radioactive and fl uorogenic transfer assays ( Table 1 , 2 ). Whereas anacetrapib and torcetrapib were potent inhibitors of both CE (IC 50 = 10 ± 4.1 and 8 ± 3.1 nM, respectively) and TG (IC 50 = 11 ± 5.9 and 7 ± 1.0 nM, respectively) transfer, dalcetrapib was approximately 27-fold less potent in inhibiting CETP-mediated neutral lipid transfer (CE IC 50 = 270 ± 38 nM; TG IC 50 = 268 ± 48 nM) ( Fig. 2A , Table 2 ). Both anacetrapib and torcetrapib continued to potently block CE and TG transfer in 95% human serum, whereas the potency of dalcetrapib was diminished >37-fold ( Fig. 2B , Table 2 ). Further preincubation of each inhibitor for 24 h did not significantly change their potencies in blocking either CE or TG transfer by CETP in 95% human serum ( Fig. 2C , Table 2 ). a The potencies of CETP inhibitors anacetrapib, torcetrapib, and dalcetrapib were determined in the fl uorogenic transfer assays as described in "Methods."
b Inhibitors were tested in reactions measuring transfer of either CE or TG.
c Concentration of CETP inhibitor at which 50% of either CE or TG transfer was inhibited; values are means ± SD.
d n.d., not determined. with the addition of a single half-molecule ( Fig. 4D ). Under identical conditions, we were unable to detect covalent labeling of CETP by anacetrapib, consistent with it being a reversible inhibitor of CETP ( Fig. 4D ) . The addition of a reducing agent (DTT) in the labeling reaction resulted in a loss of CETP labeling by dalcetrapib, confi rming that the labeling was due to disulfi de bond formation. CETP was also covalently labeled by the cysteine-modifying reagent iodoacetamide, confi rming the susceptibility of a free cysteine in CETP for modifi cation. These results confi rm that dalcetrapib covalently labels CETP via disulfi de bond formation and also demonstrates that anacetrapib does not covalently label CETP.
Dalcetrapib covalently labels bulk proteins from human and mouse plasma
Given that dalcetrapib forms a disulfi de bond with CETP and that dalcetrapib shows a signifi cant loss of inhibitory potency in the presence of 95% serum, we questioned whether dalcetrapib was capable of covalently labeling other plasma proteins. Therefore, we examined the ability of both anacetrapib and dalcetrapib to form covalent interactions with human serum proteins ( Fig. 5A ) ( Fig. 4B ). These results demonstrate that anacetrapib, torcetrapib, and dalcetrapib each compete with one another for binding CETP.
It has previously been reported that inhibition of CETP activity by dalcetrapib requires disulfi de bond formation between dalcetrapib and Cys13 of CETP ( 35, 56 ) . In contrast, torcetrapib has been shown to be a reversible inhibitor of CETP activity ( 50 ) . To measure the reversibility of anacetrapib's interaction with CETP, we used LC-MS to detect covalent labeling of CETP by dalcetrapib. When the disulfi de form of dalcetrapib ( Fig. 4C ) was incubated with CETP, a gain in mass of 318 Da was observed, consistent Fig. 2 . Inhibition of CETP-dependent CE transfer using a radioactive neutral lipid transfer assay. Increasing amounts of the indicated compounds were assayed in the in vitro radioactive assay using either 2% human serum with additional (30 nM) purifi ed N341Q CETP protein added, or in 95% human serum as described in "Methods." Inhibitors were preincubated for either 1 or 24 h before addition of LDL containing labeled tracer neutral lipids. A: Dose response of inhibitors reducing CETP-mediated CE transfer in 2% human serum. Inhibitors were preincubated with CETP in 2% human serum for 1 h before addition of a The potencies of CETP inhibitors anacetrapib, torcetrapib, and dalcetrapib were determined in the radioactive transfer assay as described in "Methods."
by guest, on August 28, 2017 www.jlr.org Downloaded from plasma from wild-type mice. Importantly, the pattern of protein labeling by dalcetrapib was similar in both wildtype and CETP Tg samples, indicating that additional proteins to CETP are covalently labeled by dalcetrapib ( Fig.  5D ). These data demonstrate that dalcetrapib, but not anacetrapib, is capable of forming covalent bonds with both human and mouse plasma proteins.
CETP inhibitors induce the formation of a complex between CETP and HDL
Torcetrapib has been shown to inhibit the neutral lipid transfer activity of CETP by inducing a stable complex between CETP and HDL ( 50, 56 ) . One method used to measure the formation of this complex is native gel electrophoresis, which can detect differences in the effective size of CETP upon binding both inhibitor and HDL. To compare the relative potencies of CETP inhibitors in blocking neutral lipid transfer and formation of a CETP-HDL complex, binding assay conditions were chosen to be similar to those used in the fl uorogenic CETP activity assay described in Fig. 1 . As shown in Fig. 6A , addition of anacetrapib results in a signifi cant shift in the apparent molecular weight of CETP due to formation of a stable complex between CETP and HDL. The potency with which anacetrapib promotes the shift in CETP's apparent molecular weight correlates with its potency in inhibiting CETPmediated neutral lipid transfer under similar conditions ( Fig. 6A , Table 1 ). In parallel, we also found that addition of either torcetrapib or dalcetrapib also results in a shift of CETP's apparent molecular weight ( Fig. 6B, C ) . Similar to its relatively weaker potency in blocking CETP neutral lipid transfer, dalcetrapib was signifi cantly less potent than both anacetrapib and torcetrapib in promoting CETP-HDL complex formation.
In addition to native gel electrophoresis, we also measured the apparent size of CETP in human plasma following treatment with anacetrapib, torcetrapib, or dalcetrapib ( Fig. 7 ) . In the absence of inhibitor, CETP eluted in a size range smaller than HDL. In contrast, when inhibitortreated human plasma was fractionated by FPLC, we found the apparent size of CETP to be greater than HDL, consistent with each inhibitor promoting the association of CETP and HDL ( Fig. 7 ) ( 50 ) . This association was consistent whether plasma was treated with anacetrapib, torcetrapib, or dalcetrapib. These data indicate that each inhibitor blocks CETP-mediated neutral lipid transfer by inducing the formation of a stable complex between CETP and HDL.
DISCUSSION
Because anacetrapib is currently in late-stage clinical development, a detailed description of its mechanism of action has not been reported. In the present study, we have conducted a detailed biochemical analysis of anacetrapib in addition to two structurally distinct CETP inhibitors, torcetrapib and dalcetrapib. Anacetrapib was a potent inhibitor of CETP-mediated neutral lipid transfer when tested in both fl uorogenic and radioactive transfer assays. ( Fig. 5B , band at ‫ف‬ 50 kDa), indicating that dalcetrapib is capable of covalently labeling additional proteins in human plasma.
We next determined if [ 14 C]dalcetrapib is capable of labeling mouse plasma proteins in either the presence or absence of CETP ( Fig. 5C ). For these studies, plasma was isolated from either wild-type C57BL/6 mice lacking CETP or from transgenic mice carrying the cynomolgus monkey CETP gene (CETP Tg ) ( 68 ) . As shown in Fig. 5C ( Fig. 5D ) . Western-blot analysis of protein samples from wild-type and CETP Tg mice confi rmed that cynomolgus CETP migrates at an apparent molecular weight of 68-71 kDa ( 69 ), which was not detected in radioactive neutral lipid transfer assay ( 64, 65 ) . In agreement with previous reports ( 35, 50 ), we found torcetrapib was a potent inhibitor of both CE and TG transfer, whereas dalcetrapib was a signifi cantly weaker inhibitor ( Table 1, 2 ). Similar to torcetrapib, anacetrapib was also a potent inhibitor of CE and TG transfer, with IC 50 values in the range of 10-17 nM when tested in 2% human serum. Inhibition of CETP by torcetrapib has been shown to be reversible and not time dependent ( 50 ) . In agreement with these fi ndings, the inhibitory potency of anacetrapib and torcetrapib was not signifi cantly affected by 24 h preincubation of compound and CETP ( Fig. 1C, 2C ). In contrast, the potency of dalcetrapib in blocking CETP-dependent transfer of CE increased 26-fold when preincubated for 24 h ( Fig. 1C ) . Thus, dalcetrapib shares the characteristic of time-dependent inhibition with a number of hydrophobic cysteine-modifying reagents ( 70, 71 ) . When tested in 95% human serum, both anacetrapib and torcetrapib were Similarly, torcetrapib was also a potent inhibitor of CETP activity, whereas dalcetrapib was a less potent inhibitor of lipid transfer. The potency of dalcetrapib in inhibiting CETP activity was also found to be time dependent and sensitive to the presence of human serum. Although anacetrapib, torcetrapib, and dalcetrapib competed with one another for binding CETP, anacetrapib's binding was reversible and dalcetrapib's binding was covalent. In addition, dalcetrapib was capable of covalently labeling both human and mouse plasma proteins. Lastly, each inhibitor was found to promote the formation of a stable CETP-HDL complex at concentrations relevant to their inhibition of neutral lipid transfer. Together, these results demonstrate that anacetrapib is a potent, reversible inhibitor of CETP that is well suited to determine the pharmacological potential of inhibiting CETP for treatment of CHD.
To determine the potency of each inhibitor in blocking CETP activity, we tested them in both a fl uorogenic and cysteine forming a disulfi de bond with dalcetrapib (Cys13) is near one end of the lipid-binding tunnel ( 72 ) . The question of whether or not each CETP inhibitor binds an overlapping site on CETP awaits X-ray structural determination of a CETP-inhibitor complex. Previous reports using sitedirected mutagenesis have suggested that dalcetrapib, in addition to other cysteine-modifying reagents, requires disulfi de bond formation with Cys13 of CETP to inhibit activity ( 35, 71 ) . In addition, direct evidence for dalcetrapib modifying Cys13 of CETP was recently obtained using peptide mapping and MS ( 56 ) . Using MS, we confi rmed that CETP is modifi ed by a single half-molecule of the dalcetrapib disulfi de inhibitor and that this modifi cation is dependent on disulfi de bond formation ( Fig. 4D ) . In addition, we also confi rmed that anacetrapib does not covalently modify CETP.
somewhat less potent (4-to 5-fold) in blocking neutral lipid transfer, while the potency of dalcetrapib was reduced by >37-fold ( Fig. 2B , Table 2 ). This apparent loss of activity in 95% serum indicates that dalcetrapib may be more likely than anacetrapib and torcetrapib to bind plasma proteins or lipoproteins.
Using a modifi ed CETP binding assay ( 50 ), we found that anacetrapib, torcetrapib, and dalcetrapib each compete with one another for binding CETP. ( Fig. 4A, B ) . Although these results demonstrate competition in binding CETP, they do not address the manner of such competition (direct vs. indirect) or the location of inhibitor binding CETP. Based on the crystal structure of CETP, the Biacore studies demonstrating that preincubation of CETP with dalcetrapib prevented the interaction of CETP and an immobilized analog of torcetrapib ( 56 ) .
Incubation of dalcetrapib in 95% human serum significantly decreased its potency in inhibiting CETP neutral lipid transfer ( Fig. 2B ). In addition, dalcetrapib was confi rmed to covalently label CETP ( Fig. 4D ) , presumably via a disulfi de bond with Cys13. Together, these fi ndings suggest that dalcetrapib may be capable of covalently labeling additional proteins with accessible cysteines. To determine whether dalcetrapib and anacetrapib are capable of covalently labeling plasma proteins, we incubated [ 14 C]labeled inhibitors with human plasma and determined the levels of covalent protein labeling ( Fig. 5 ) . Dalcetrapib was found to covalently label human plasma proteins in both a time-and concentration-dependent manner, whereas there was no evidence of protein labeling by anacetrapib ( Fig. 5A ) . Similar results were also observed with plasma from both wild-type and CETP Tg mice ( Fig. 5C ). While qualitative, imaging of [ 14 C]labeled proteins by nonreducing SDS-PAGE suggests that CETP is not the only protein covalently labeled by dalcetrapib ( Fig. 5B, D ) . While it is expected that CETP will be labeled in human plasma or in plasma from CETP Tg mice, evidence in support of dalcetrapib labeling additional proteins includes: 1 ) the apparent While this report was under preparation, Maugeais et al. ( 73 ) reported that dalcetrapib did not compete with either anacetrapib or torcetrapib for binding CETP. It is important to note key differences between the two CETPinhibitor binding studies. Binding studies in the present report were carried out in solution under conditions similar to the CETP activity assay. As previously described, the apparent binding affi nities of both [ 3 H]anacetrapib and [ 3 H]torcetrapib for CETP under these conditions were similar to their potencies in blocking CETP activity ( Fig.  1A, 3B ). In addition, the potencies of torcetrapib, anacetrapib, and dalcetrapib (EC 50 ( Fig. 1A, 4A, B ) . In studies described by Maugeasis et al., ( 73 ) inhibitor binding was measured using CETP that was fi rst immobilized to Sepharose or by amine coupling to a Biacore sensor chip. Both the nonspecifi c immobilization of CETP on a solid surface and the immobilization conditions used (e.g., low pH) could alter the interaction between CETP and inhibitors. For example, specifi c binding pockets for each inhibitor could be altered, or nonspecifi c binding sites could be introduced due to partial denaturing or unfolding of immobilized CETP. In addition, our results are in agreement with previously reported ( Fig. 6 ). This mode of inhibition was also observed with a structurally distinct N,N -disubstituted trifl uoro-3-amino-2-propanol CETP inhibitor (Searle 1) ( 50 ). In the clinic, treatment of human subjects with anacetrapib, torcetrapib, or dalcetrapib has also been shown to increase the concentration of CETP in circulation despite inhibiting CETP activity ( 51, 67, 75 ) . This increase in CETP concentration has been postulated to be due to an increased association of CETP with HDL, thereby resulting in CETP taking on a signifi cantly longer half-life (76) (77) (78) . These results demonstrate that despite their biochemical differences (e.g., differences in potency, reversible vs. irreversible binding), each CETP inhibitor tested prevents CETP from being released from its lipoprotein substrate.
In summary, these studies describe the biochemical characterization of the CETP inhibitors anacetrapib, torcetrapib, and dalcetrapib and compare their effects on CETP inhibition and protein binding. We fi nd that anacetrapib and torcetrapib potently block both CE and TG transfer activities of CETP. Dalcetrapib was a comparably weaker inhibitor of CETP in vitro and displayed time-dependent inhibition of CETP neutral lipid transfer activity. Although each inhibitor competed for binding purifi ed CETP, both anacetrapib and torcetrapib bound reversibly and dalcetrapib bound CETP covalently, in agreement with its timedependent inhibition. Using a covalent plasma labeling assay, we also found that dalcetrapib covalently labels both human and mouse plasma proteins other than CETP. Each of the inhibitors tested promoted formation of a stable complex between CETP and HDL, indicating that the formation of a complex between CETP and HDL is a key mechanism whereby these inhibitors block CETP transfer activity. Together, these fi ndings detail both shared characteristics of tested CETP inhibitors, such as blocking both CE and TG transfer and promoting CETP-HDL complex formation, and also demonstrate differences between them, such as noncovalent versus covalent binding to CETP and covalent labeling of bulk plasma proteins. Further clinical studies are needed to determine whether the observed changes in lipids in response to CETP inhibition will translate into an improved clinical benefi t in patients with dyslipidemia. molecular weights of predominant [
14 C]labeled proteins do not overlap with the expected size of CETP ( Fig. 5B, D ) ; 2 ) equivalent levels of protein labeling were observed in plasma samples from both wild-type mice lacking CETP and CETP Tg mice ( Fig. 5C ) the pattern of labeled proteins was identical from both wild-type and CETP Tg mouse plasma samples ( Fig. 5D ). In addition, MD-2, a part of the Toll-like 4 signaling cascade, was recently shown to be modifi ed by dalcetrapib in addition to other hydrophobic compounds with a cysteine-reactive group ( 74 ) . Altogether, these results indicate that dalcetrapib is capable of covalently labeling both CETP and additional plasma proteins.
Given the differences in the nature of CETP binding by these inhibitors, with dalcetrapib being an irreversible inhibitor and the other two being reversible , it seems possible they might exhibit different mechanisms of inhibition. Clark et al. ( 50 ) reported that torcetrapib inhibits CETP neutral lipid transfer via the promotion of a stable complex between CETP and HDL. In agreement with this fi nding, the addition of increasing amounts of torcetrapib resulted in CETP-HDL complex formation, as determined using both native PAGE and FPLC ( Fig. 6B, 7 ) . We also found that both anacetrapib and dalcetrapib promote the formation of a higher molecular weight CETP-HDL complex ( Fig. 6A, C, 7 ) . No inhibitor, at any concentration, changed the mobility of CETP in the absence of HDL (data not shown). Consistent with the interpretation that the formation of a CETP-HDL complex is part of the inhibitory mechanism of these inhibitors, the IC 50 of each inhibitor in the fl uorogenic neutral lipid transfer assay strongly correlates with the concentration of inhibitor required to cause one-half of the CETP to complex with 
